Literature DB >> 11479429

The morphology, immunophenotype and distribution of paracortical dendritic leucocytes in lymph nodes regional to cutaneous melanoma.

A M Lana1, D R Wen, A J Cochran.   

Abstract

Our aim was to identify and delineate alterations in the distribution and immunophenotype of the lymphocytes and paracortical dendritic leucocytes (interdigitating dendritic cells; IDCs) in lymph nodes regional to tumours. Using immunocytochemistry and computer-assisted image analysis we examined 65 lymph nodes excised from 47 patients with malignant melanoma. Twenty-nine patients had American Joint Committee on Cancer (AJCC) stage II melanoma (no tumour spread beyond the primary site) and 18 had AJCC stage III disease (metastases in the regional nodes). There were significant differences in the frequency, morphology, immunophenotype and anatomical distribution of the IDCs and in the complexity of their dendritic processes in different areas within individual lymph nodes. We conclude that morphological and phenotypical variations in IDCs correlate with differing levels of antigen presentation. Downregulation of antigen presentation in lymph nodes regional to tumours is most probably mediated by tumour products. Differences in IDC distribution and characteristics in lymph nodes from different anatomical sites must be considered in interpreting studies of nodal morphology and function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479429     DOI: 10.1097/00008390-200108000-00011

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  9 in total

Review 1.  The lymph node pre-metastatic niche.

Authors:  Jonathan P Sleeman
Journal:  J Mol Med (Berl)       Date:  2015-11       Impact factor: 4.599

2.  Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells.

Authors:  Barbara G Molenkamp; Ronald J C L M Vuylsteke; Paul A M van Leeuwen; Sybren Meijer; Wim Vos; Pepijn G J T B Wijnands; Rik J Scheper; Tanja D de Gruijl
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

3.  Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model.

Authors:  John R Ohlfest; Brian M Andersen; Adam J Litterman; Junzhe Xia; Christopher A Pennell; Lauryn E Swier; Andres M Salazar; Michael R Olin
Journal:  J Immunol       Date:  2012-12-17       Impact factor: 5.422

4.  Presence and phenotype of dendritic cells in uveal melanoma.

Authors:  Marta E Polak; Nicola J Borthwick; Penny Johnson; John L Hungerford; Bernie Higgins; Silvana Di Palma; Martine J Jager; Ian A Cree
Journal:  Br J Ophthalmol       Date:  2007-03-08       Impact factor: 4.638

5.  IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence.

Authors:  Eijun Itakura; Rong-Rong Huang; Duan-Ren Wen; Eberhard Paul; Peter H Wünsch; Alistair J Cochran
Journal:  Mod Pathol       Date:  2011-02-11       Impact factor: 7.842

6.  Activation of tonsil dendritic cells with immuno-adjuvants.

Authors:  Marta E Polak; Nicola J Borthwick; Francis G Gabriel; Martine J Jager; Ian A Cree
Journal:  BMC Immunol       Date:  2008-03-18       Impact factor: 3.615

7.  Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC.

Authors:  Caroline Tosch; Bérangère Bastien; Luc Barraud; Benoit Grellier; Virginie Nourtier; Murielle Gantzer; Jean Marc Limacher; Eric Quemeneur; Kaïdre Bendjama; Xavier Préville
Journal:  J Immunother Cancer       Date:  2017-09-19       Impact factor: 13.751

Review 8.  Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy.

Authors:  Simone Nüssing; Joseph A Trapani; Ian A Parish
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

9.  Mechanisms of local immunosuppression in cutaneous melanoma.

Authors:  M E Polak; N J Borthwick; F G Gabriel; P Johnson; B Higgins; J Hurren; D McCormick; M J Jager; I A Cree
Journal:  Br J Cancer       Date:  2007-06-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.